Phase II
Sponsors
European Institute of Oncology, KK Women's and Children's Hospital, GeneQuantum Healthcare (Suzhou) Co., Ltd., Suzhou Genhouse Bio Co., Ltd., Roche Nederland B.V.
Conditions
Advanced Malignant Solid TumorsAdvanced Solid Tumor CancerAsthma
Severe corticosteroid dependent AsthmaBreast CancerCARCrohn syndrome
regional enteritisLymphoblastic LeukemiaLymphoblastic Leukemia in Children
Phase 1
Dual Anti-CD22/CD19 Chimeric Antigen Receptor-directed T Cells (CART2219.1) for Relapsed Refractory B-Lineage Leukaemia
NCT05429905
Start: 2022-07-18End: 2025-12-31Target: 48Updated: 2023-03-09
A Study of GQ1010 in Subjects With Advanced Solid Tumors
RecruitingNCT06464055
Start: 2024-05-23End: 2028-12-31Target: 260Updated: 2025-02-10
A Study to Evaluate Safety, PK and Efficacy of GH55 in Combination With GH21 in Patients With Solid Tumors
Not yet recruitingNCT07446725
Start: 2026-02-24End: 2029-12-31Target: 152Updated: 2026-03-03
Phase 2
A PHASE II, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, MULTICENTER TRIAL TO ASSESS THE ORAL CORTICOSTEROID*SPARING EFFECT OF LEBRIKIZUMAB IN PATIENTS WITH SEVERE CORTICOSTEROID-DEPENDENT ASTHMA.
Active, not recruitingNL-OMON42207
Start: 2015-09-09Target: 15Updated: 2024-02-28
A Multicenter, Randomized, Double-Blind, Placebo-Controlled Study of ABT-494 for the Induction of Symptomatic and Endoscopic Remission in Subjects with Moderately to Severely Active Crohn's Disease who have Inadequately Responded to or are Intolerant to Immunomodulators or Anti-TNF Therapy
Active, not recruitingNL-OMON44996
Start: 2016-01-06Target: 22Updated: 2024-02-28